SCHEMBL23360767

SCHEMBL23360767

O=C(O)C1C=C2CCCC2N1

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
OAT P04181 1/20 0.34
EGLN1 Q9GZT9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25320147 0.67 EGLN1 (0.31) EGLN1
SCHEMBL25427716 0.61
SCHEMBL2344195 0.56 CAD (0.43)
SCHEMBL630497 0.56 CAD (0.43)
SCHEMBL3625069 0.56 CAD (0.43)
SCHEMBL28321908 0.55
SCHEMBL1355425 0.55 OAT (0.60) OAT
SCHEMBL9845677 0.55 OAT (0.37) OAT
SCHEMBL10777579 0.55 OAT (0.37) OAT
SCHEMBL31289649 0.55 DPP4 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022117893-A2 COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA S-FORM PHARMA (BE) 2022-06-09 WO claimed
WO-2022117893-A2 COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA S-FORM PHARMA (BE) 2022-06-09 WO disclosed
US-20210145964-A1 STROMA-TARGETING TREATMENT FOR PATIENTS WITH ELEVATED ADAM12 LEVELS ACADEMISCH MEDISCH CENTRUM (NL) 2021-05-20 US disclosed